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Abstract
Copy number alterations (CNAs) are among the most common molecular events in human prostate cancer genomes and are associated with worse prognosis. Identification of the oncogenic drivers within these CNAs is challenging due to the broad nature of these genomic gains or losses which can include large numbers of genes within a given region. Here we profiled the genomes of four genetically engineered mouse prostate cancer models that reflect oncogenic events common in human prostate tumors, with the goal of integrating these data with human prostate cancer datasets to identify shared 
Introduction
The development of high-throughput genomic platforms has allowed comprehensive profiling of human malignancies with the goal of identifying oncogenic driver events that may impact our understanding of the biology of cancer and ultimately improve patient management. Studies profiling primary and metastatic prostate cancer have identified a number of established and novel oncogenic events in prostate cancer, including loss of the tumor suppressors PTEN and TP53, genomic rearrangements of ERG, amplification of MYC, focal loss of chromosome 3p, and mutations in SPOP (1) (2) (3) .
Genomic studies efficiently identify oncogenes or tumor suppressors when specific genes are frequently mutated or have focal gain or loss. However, the utility of this approach is limited when broad regions of genomic gain or loss are present because of the large number of genes impacted. Furthermore, these broad genomic gains and losses could simply be a consequence of genomic instability rather than playing a causal role in the cancer. Interestingly, tumors that develop in genetically engineered mouse (GEM) models often do not have the same complexity of copy number alterations as their human counterparts, unless these mice are crossed into strains with genetically unstable backgrounds (4) . The relative simplicity of murine tumor genomes provides a convenient opportunity to conduct integrative mouse-human tumor genomic analysis to identify critical human tumor drivers (5, 6) .
Several GEM models of prostate cancer have been developed which faithfully recapitulate the oncogenic driving genomic alterations and histopathology of prostate cancer. While these model systems to date have not faithfully recapitulated the metastatic disease process several of these GEM models indeed model genetic events enriched in both primary and metastatic prostate cancer. We elected to use 4 GEM models most representative of the common genomic alterations present in prostate cancer. PB-MYC mice, model amplification and over-expression of MYC observed in human prostate cancer (7) . These mice develop high grade prostatic intra-epithelial neoplasia (HGPIN) by 2 months of age which progresses to established invasive adenocarcinoma by 12 months of age. Pten prostate conditional null mice (Pten lox/lox months of age (8) PB-Cre) demonstrate HGPIN by 2 months of age with progression to invasive adenocarcinoma by 6 months of age (10) .
Here we applied this integrative mouse-human tumor genomics strategy to prostate cancer. Using these four genetically engineered mouse models that reflect common driver alterations found in human tumors (7-10), we found that the gene encoding the Met receptor tyrosine kinase was frequently amplified in murine prostate tumors initiated by loss of the tumor suppressors Pten and p53. Analysis of publically available genomic data sets of human prostate cancer and revealed MET amplification in approximately 30% of metastatic cases but rarely in primary tumors. Importantly, Met copy number gain and expression in Met-amplified tumors is heterogeneous. Thus, while MET inhibition impairs the growth of MET-amplified tumors, intratumoral heterogeneity compromises long-term therapeutic efficacy. These findings have implications for ongoing clinical trials of MET inhibitors in advanced prostate cancer.
Materials and Methods
Mouse models of prostate cancer
The GEM models of human prostate cancer (PB-MYC, Pten 
Cell Lines
The cell lines used in our experiments included the MYC CaP line derived from a PB-MYC mouse by Sawyers' lab, the CaP8 line derived from a Pten 
Molecular profiling
Array CGH
DNA was isolated, quantified using the Thermo Scientific NanoDrop 1000
Spectrophotometer, and submitted to our Genomics Core Laboratory for array CGH submitted for CGH analysis. Reference DNA was prepared from the prostates of genotype/strain matched wild-type littermate mice. All DNA met the requirements of an A260/280 ratio of 1.6 -1.8 and a concentration greater than 150 ug/ul. Three micrograms of tumor and reference DNA was digested and labeled by random priming using the Bioprime kit (Invitrogen). Labeled DNA was hybridized to the mouse Agilent 244K CGH array and the slides were scanned and images quantified using Feature Extraction 9.1 (Agilent). Raw data from the Agilent mouse 244K CGH array were normalized as previously described and probe level data was segmented with Circular Binary Segmentation and analyzed with RAE.
Transcriptome profiling
Total RNAs were isolated and quantified using the Thermo Scientific NanoDrop 1000
Spectrophotometer. RNA samples with an A260/280 ratio of >1. 8 mice. Quality of the RNA was assessed by the RNA 6000 picoAssay and a RIN number > 7.0 was considered adequate for labeling. A total of 300 ng of RNA was labeled and hybridized on the Illumina MouseRef-8 v2 bead arrays. Raw data were Log2 transformed and normalized. Gene Set Enrichment Analysis (GSEA) was performed to determine gene sets disproportionally over-or under-expressed in groups stratified by specific copy number alterations. Hierarchial clustering was carried out on genes meeting the criteria of greater than 3 fold change across more than two samples using Pearson correlation with pairwaise complete linkage.
FISH analyses
FISH analysis was performed on formalin fixed paraffin embedded (FFPE) sections using a two-color probe mix. The probe mix consisted of BAC clones containing the full length 
Human prostate cancer molecular profiling
The human prostate cancer data sets used herein have been previously published (3). The complete genomics dataset and analytic methods is reported separately and is available analyzed independently for primary tumor and metastatic lesions. Student's t-test was used to identify association between copy number alteration of HGF and MET. GSEA was performed as previously described above.
In vitro experiments
In vitro experiments were conducted using the LAPC4 cell line. The LAPC4 cell lines were infected and selected with RFP control and MET expressing virus and selected with puromycin. Proliferation assays were conducted by plating 1x10 hours for protein evaluation and as part of a cell proliferation assay. Cell lysates for western blot analysis were prepared using standard RIPA buffer. All experiments were conducted in triplicate and standard deviations were reported.
Pre-clinical in vivo studies
Xenograft Model
For xenograft experiments, 1x10 6 LAPC4-RFP and LAPC4-MET cells were injected into the bilateral flanks of SCID mice (10 mice per group) and tumor volumes were measured weekly over 28 days. At the end of study mice were euthanized and tumor tissue was procured for FFPE. Representative slides were evaluated by H&E staining and used for immunohistochemical analyses.
GEM prostate cancer transplant model
Prostate tumors from Pten p53 null mice were harvested at 6 months of age, dissected into 2 x 2 x 2 mm cubes and transplanted into the unilateral flank of athymic mice.
Growth of these tumors was demonstrated by measuring tumor volume over 16 days.
Animals were euthanized and specimens were procured for FFPE. Transplanted mice were randomized to receive vehicle control or crizotinib (Pfizer, 50 mg/kg/day) and tumor volumes were measured weekly over 21 days. At the end of study mice were euthanized and tumors were procured by FFPE for H&E and immunohistochemical staining. Similar studies were conducted using our Rosa-26-ERG Pten 
Accession number
NIH NCBI Gene Expression Omnibus (GEO) Agilent aCGH GEO accession number is GSE61382
Illumina microarray expression GEO accession number is GSE61382 
Results
Recurrent amplification of Met in
We also found that two other focally amplified genes in mouse tumors, Jun and Yap1, were also amplified in 3-5% and 10-11% of human metastatic prostate cancers, respectively (Figure 2A, 2C ). Thus analysis of murine prostate cancer genomes resulted in the identification of molecular events in human prostate cancer that are easily overlooked by "human only" genome studies.
Met amplification is heterogeneous within individual tumors
To evaluate the impact of Met amplification on Met expression, protein and RNA were harvested from our murine prostate tumor specimens previously analyzed by array CGH. Expression analysis (Illumina) was performed in a subset of prostate cancer specimens analyzed for CNAs. As expected, unsupervised clustering of genes differentially regulated across the GEM tumor specimens was primarily driven by genotype ( Figure S3B ). In accordance with the loss of PTEN and TP53 being enriched in human metastatic prostate cancers, modeling loss of Pten and p53 in GEM models of prostate cancer revealed enrichment of gene signatures associated with metastasis, although these murine tumors do not display a metastatic phenotype (Table S3 ). While this is likely secondary to differences in the biology of mouse and humans, and potentially the acquirement of secondary drivers of metastasis, our study reveals that there is molecular similarity when modeling metastatic alterations in primary murine prostate cancers, and thus may provide a pre-clinical model system to study therapies targeting metastatic prostate cancer. Figure 5D ). Over a 14 day period the tumors engrafted and grew rapidly. These tumors were further passaged into athymic mice, then treated with the MET inhibitor crizotinib (50 mg/kg/day) or vehicle control. Tumors from Pten ERG mice, which lack Met amplification, were also studied to explore whether the effect of crizotinib was context specific. Pten/ p53 tumors treated with crizotinib had a significant reduction in growth rate whereas Pten/ERG tumors were unaffected (p-value<0.01) ( Figure 5D , 5E, S4B). Inhibition of MET in Pten/p53 tumors was associated with reduced levels of pAkt and ki67 ( Figure 5E ). Thus, inhibition of MET specifically impairs the growth of murine prostate cancers known to harbor amplification or overexpression of Met.
Tumors with high level
To directly evaluate the impact of Met amplification on tumor response, we conducted an additional experiment in which FISH analysis for Met amplification was performed. Pten p53 tumors were grafted into mice and treated with crizotinib ( Figure   6A ). Tumors harboring predominantly diploid copies of Met had the least response, while tumors harboring Met amplification had the greatest response ( Figure 6A, 6B, 6C ). Figure 6D, 6E) .
Discussion
Through the genomic profiling of prostate cancer GEM models we identified several recurrent molecular events that develop during the evolution of murine prostate cancer. Integrating this murine data with genomic data from human prostate cancer led us to identify MET amplification as a molecular alteration with a high probability of playing a functional role in prostate cancer progression. Importantly, MET amplification did not emerge as a prostate cancer driver lesion using traditional human tumor genome analysis pipelines. However, reevaluation of the human tumor data based on our (22, 24, 25) . This discrepancy suggests the bone scan effect of cabozantib may occur through inhibition of a target in the bone microenvironment whereas the antitumor effect may be a consequence of target inhibition in tumor cells.
Our data offer a potential explanation for these discrepant clinical response rates, specifically that MET amplification could be associated with tumor response but not bone scan response. One prediction from our data is that MET inhibition would inhibit tumor 
data also suggest that these responses may be short lived due to the intratumoral heterogeneity of Met-amplification we observed in the mouse tumors.
In summary, our work demonstrates the potential of integrated human and GEM model genomic profiling of prostate cancer to provide insight into new biologic drivers acquired during tumor progression, as illustrated by our discovery of Met amplification.
Additional genomic alterations uncovered by this analysis, such as Jun and Yap1, also merit further evaluation.
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